CR9257A - Polimorfo cci-779 y uso del mismo - Google Patents
Polimorfo cci-779 y uso del mismoInfo
- Publication number
- CR9257A CR9257A CR9257A CR9257A CR9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A CR 9257 A CR9257 A CR 9257A
- Authority
- CR
- Costa Rica
- Prior art keywords
- cci
- polymorph
- provides
- preparing
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invencion proporciona el polimorfo forma II de CCI-779; esta invencion tambien proporciona procedimientos para preparar el polimorfo forma II de CCI-779 y composiciones farmaceuticas que incluyen el polimorfo forma II de CCI-779.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65137405P | 2005-02-09 | 2005-02-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR9257A true CR9257A (es) | 2007-11-23 |
Family
ID=36570939
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR9257A CR9257A (es) | 2005-02-09 | 2007-07-18 | Polimorfo cci-779 y uso del mismo |
Country Status (19)
Country | Link |
---|---|
US (1) | US7442707B2 (es) |
EP (1) | EP1856130A1 (es) |
JP (1) | JP2008530090A (es) |
KR (1) | KR20070107030A (es) |
CN (1) | CN101115759A (es) |
AR (1) | AR052479A1 (es) |
AU (1) | AU2006213061A1 (es) |
BR (1) | BRPI0607932A2 (es) |
CA (1) | CA2595766A1 (es) |
CR (1) | CR9257A (es) |
GT (1) | GT200600044A (es) |
IL (1) | IL184560A0 (es) |
MX (1) | MX2007009590A (es) |
NO (1) | NO20073725L (es) |
PE (1) | PE20060996A1 (es) |
RU (1) | RU2007129264A (es) |
TW (1) | TW200638932A (es) |
WO (1) | WO2006086172A1 (es) |
ZA (1) | ZA200706628B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8551512B2 (en) | 2004-03-22 | 2013-10-08 | Advanced Cardiovascular Systems, Inc. | Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS |
EP1957500A1 (en) * | 2005-12-07 | 2008-08-20 | Wyeth a Corporation of the State of Delaware | Process for the preparation of purified crystalline cci-779 |
US7622578B2 (en) * | 2005-12-07 | 2009-11-24 | Wyeth | Scalable process for the preparation of a rapamycin 42-ester from a rapamycin 42-ester boronate |
AR058283A1 (es) * | 2005-12-07 | 2008-01-30 | Wyeth Corp | Metodos para la preparacion de rapamicina cristalina y para la medicion de la cristalinidad de los compuestos de rapamicina utilizando calorimetria diferencial de barrido |
TW200824713A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Processes for the synthesis of individual isomers of mono-PEG CCI-779 |
CN102282457A (zh) * | 2009-01-21 | 2011-12-14 | 拜康有限公司 | 确定西罗莫司稳定性的方法和制备其稳定形式的工艺 |
US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
CN109020995A (zh) * | 2017-06-12 | 2018-12-18 | 鲁南制药集团股份有限公司 | 一种替西罗莫司的晶型物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US6277983B1 (en) * | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
TWI256395B (en) | 1999-09-29 | 2006-06-11 | Wyeth Corp | Regioselective synthesis of rapamycin derivatives |
US6680330B2 (en) * | 2001-08-22 | 2004-01-20 | Wyeth | Rapamycin dialdehydes |
WO2003018573A1 (en) | 2001-08-22 | 2003-03-06 | Wyeth | Rapamycin 29-enols |
BRPI0412659A (pt) * | 2003-07-16 | 2006-09-26 | Wyeth Corp | isÈmero c de cci-779, seu processo de preparação, composição farmacêutica compreendendo o mesmo e pacote farmacêutico contendo o referido composto |
WO2005016935A2 (en) * | 2003-08-07 | 2005-02-24 | Wyeth | Regioselective synthesis of cci-779 |
BRPI0414066A (pt) * | 2003-09-03 | 2006-10-24 | Wyeth Corp | 42-éster de rapamicina amorfo com ácido 3-hidróxi-2-( hidroximetil )-2-metilproipiÈnico e composições farmacêuticas que o contenha |
WO2005105811A1 (en) * | 2004-04-14 | 2005-11-10 | Wyeth | Regiospecific synthesis of rapamycin 42-ester derivatives |
-
2006
- 2006-01-25 MX MX2007009590A patent/MX2007009590A/es not_active Application Discontinuation
- 2006-01-25 BR BRPI0607932A patent/BRPI0607932A2/pt not_active IP Right Cessation
- 2006-01-25 CA CA002595766A patent/CA2595766A1/en not_active Abandoned
- 2006-01-25 US US11/339,728 patent/US7442707B2/en not_active Expired - Fee Related
- 2006-01-25 KR KR1020077018347A patent/KR20070107030A/ko not_active Application Discontinuation
- 2006-01-25 RU RU2007129264/04A patent/RU2007129264A/ru not_active Application Discontinuation
- 2006-01-25 CN CNA200680004408XA patent/CN101115759A/zh not_active Withdrawn
- 2006-01-25 EP EP06734012A patent/EP1856130A1/en not_active Withdrawn
- 2006-01-25 WO PCT/US2006/003098 patent/WO2006086172A1/en active Application Filing
- 2006-01-25 AU AU2006213061A patent/AU2006213061A1/en not_active Abandoned
- 2006-01-25 JP JP2007555124A patent/JP2008530090A/ja not_active Withdrawn
- 2006-02-03 PE PE2006000136A patent/PE20060996A1/es not_active Application Discontinuation
- 2006-02-06 TW TW095103902A patent/TW200638932A/zh unknown
- 2006-02-07 GT GT200600044A patent/GT200600044A/es unknown
- 2006-02-08 AR ARP060100451A patent/AR052479A1/es unknown
-
2007
- 2007-07-12 IL IL184560A patent/IL184560A0/en unknown
- 2007-07-18 NO NO20073725A patent/NO20073725L/no not_active Application Discontinuation
- 2007-07-18 CR CR9257A patent/CR9257A/es not_active Application Discontinuation
- 2007-08-08 ZA ZA200706628A patent/ZA200706628B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MX2007009590A (es) | 2007-09-12 |
KR20070107030A (ko) | 2007-11-06 |
AR052479A1 (es) | 2007-03-21 |
US20060178392A1 (en) | 2006-08-10 |
US7442707B2 (en) | 2008-10-28 |
EP1856130A1 (en) | 2007-11-21 |
WO2006086172A1 (en) | 2006-08-17 |
IL184560A0 (en) | 2007-10-31 |
AU2006213061A1 (en) | 2006-08-17 |
NO20073725L (no) | 2007-09-05 |
CN101115759A (zh) | 2008-01-30 |
BRPI0607932A2 (pt) | 2016-11-08 |
CA2595766A1 (en) | 2006-08-17 |
JP2008530090A (ja) | 2008-08-07 |
TW200638932A (en) | 2006-11-16 |
PE20060996A1 (es) | 2006-11-13 |
ZA200706628B (en) | 2010-01-27 |
GT200600044A (es) | 2006-11-09 |
RU2007129264A (ru) | 2009-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR8929A (es) | Polimorfo ii de rapamicina y usos del mismo | |
CR9257A (es) | Polimorfo cci-779 y uso del mismo | |
CL2007002733A1 (es) | Compuestos derivados de 2-aril-6-fenil-imidazo[1,2-a]piridinas; procedimiento de obtencion de los compuestos; composicion farmaceutica; y uso para el tratamiento y prevencion de enfermedades neurodegenerativas, osteoporosis y cancer. | |
HN2008000311A (es) | Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida | |
CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
GT200900201A (es) | Formulaciones para el tratamiento del cáncer. | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
ATE528989T1 (de) | Kristalline feste rasagilin-base | |
CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
ECSP077316A (es) | Compuestos imidazo-3-il-amina bicíclicos sustituidos | |
CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
PA8693101A1 (es) | Compuestos de isoindol-imida y composiciones que los incluyen y mètodos para su uso | |
CL2015002635A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
ECSP099445A (es) | Quinazolinas para la inhibición de pdk1 | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
PA8667201A1 (es) | Nuevos compuestos farmaceuticos | |
CL2007002641A1 (es) | Compuestos derivados de pirimidinas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de trastornos alergicos, autoinmunes, enfermedades inflamatorias. | |
CR11861A (es) | Compuestos organicos | |
PA8778601A1 (es) | Inhibidores de la unión entre hdm2 y el proteasoma | |
CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
ATE530170T1 (de) | Paliperidonformulierung mit verzögerter freisetzung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal (granting procedure) |